GEIS-SEHOP clinical practice guidelines for the treatment of rhabdomyosarcoma
Clin. transl. oncol. (Print)
; 23(12): 2460-2473, dec. 2021.
Article
in English
| IBECS
| ID: ibc-224103
Responsible library:
ES1.1
Localization: ES15.1 - BNCS
ABSTRACT
Rhabdomyosarcoma (RMS) is the most frequent soft tissue sarcoma (STS) in children and adolescents. In Spain the annual incidence is 4.4 cases per million children < 14 years. It is an uncommon neoplasm in adults, but 40% of RMS are diagnosed in patients over 20 years of age, representing 1% of all STS in this age group. RMS can appear anywhere in the body, with some sites more frequently affected including head and neck, genitourinary system and limbs. Assessment of a patient with suspicion of RMS includes imaging studies (MRI, CT, PET-CT) and biopsy. All patients with RMS should receive chemotherapy, either at diagnosis in advanced or metastatic stages, or after initial resection in early local stages. Local control includes surgery and/or radiotherapy depending on site, stage, histology and response to chemotherapy. This guide provides recommendations for diagnosis, staging and treatment of this neoplasm (AU)
Search on Google
Collection:
National databases
/
Spain
Database:
IBECS
Main subject:
Rhabdomyosarcoma
/
Positron Emission Tomography Computed Tomography
Limits:
Humans
Country/Region as subject:
Europa
Language:
English
Journal:
Clin. transl. oncol. (Print)
Year:
2021
Document type:
Article
Institution/Affiliation country:
Gregorio Marañón University Hospital (Madrid)/Spain
/
Hospital Universitario La Paz (Madrid)/Spain
/
Pediatric Hospital Virgen del Rocío (Sevilla)/Spain
/
University Hospital Fundación Jimenez Díaz (Madrid)/Spain
/
University Hospital La Fe (Valencia)/Spain
/
Vall DHebron University Hospital (Barcelona)/Spain
/
Vall DHebron University Hospital/Spain